The worldwide exclusive license
agreements were signed with
Ramot at Tel Aviv University and
The Technion Research and
Development Foundations (TRDF)
respectively. BioLineRx plans to develop the projects
through BioLine Innovations Jerusalem (BIJ) under the
National Biotech Grant received in November 2004
from the Israeli Office of the Chief Scientist. BL-2050
has already received approval for entry into the BIJ
program and BL-2060 will be submitted for review in
the coming weeks.
BL-2050 is a novel drug candidate that has
demonstrated in animal models the ability to grow
new, stable, functional blood vessels in an ischemic
environment.
BL-2060, licensed from TRDF, is a breakthrough
approach to treating bacterial infections, developed
by Professor Amram Mor, a member of the Technion
Faculty of Biotechnology. Antibacterial peptides have
been well known as potent molecules although their
systemic use has been limited due to problems of
hemolysis. Using his novel system, Professor Mor
has generated antibacterial peptides that kill bacteria
without causing hemolysis, making this potent class of
molecules available for systemic use.
BioLineRx also announced progress on its other
pipeline candidates that are advancing toward
human clinical trials. BL-1020, BioLineRx's first in
class antipsychotic for schizophrenia, is on track for
entering human clinical trials in 2006, and was recently
presented at the Israeli Society for Neuroscience
meeting in Eilat, Israel. BL-1040, BioLineRx's novel
treatment for myocardial infarction was the subject of
a late breaking abstract at the recent American Heart
Association meeting in Dallas, Texas.
BioLineRx, Ltd., Israeli drug development company,
announced that it has signed two license agreements
for the development and commercialization of BL-2050,
for the treatment of peripheral vascular disease (PVD)
and BL-2060, a novel antibiotic.